Lead Compound Discovery from Engineered Analogs of Occidiofungin

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI131792-01
Agency Tracking Number: R41AI131792
Amount: $224,939.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA16-303
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-02-15
Award End Date (Contract End Date): 2018-01-31
Small Business Information
606 COACHLIGHT CT, College Station, TX, 77845-8145
DUNS: 078514829
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (979) 703-1517
Business Contact
Phone: (855) 384-7266
Email: james.smith@sanochemicals.com
Research Institution
 Nonprofit college or university
Project Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occidiofungin has a novel mechanism of action Occidiofungin is a potent antifungal against fluconazole and caspofungin resistant Candida albicans Occidiofungin triggers cell death by inducing apoptosis in yeast cells Occidiofungin has minimal toxicity in mice dosed with mg kg in a day toxicity study Furthermore occidiofungin was shown to reduce Candida glabrata load in the kidneys of infected mice All these studies point to the need to further the preclinical development of this novel compound A major need for furthering investigational studies on this unique antifungal compound is the identification of a lead molecule for preclinical testing The goal of this application is to screen a library of natural and semi synthetic analogs of occidiofungin for bioactivity testing The compound that has the best properties will be used in the required preclinical tests that are compulsory before our initial meeting with the FDA This work is necessary for furthering additional studies aimed at developing the antifungal compound as a new therapeutic Project Narrative The proposal addresses the need for the development of a novel broad spectrum antifungal for the treatment of systemic fungal infections We will isolate natural analogs and produce semi synthetic analogs of the antifungal occidiofungin This works is essential for identifying a lead compound for preclinical studies that are needed for filing an Investigational New Drug IND application

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government